CGI Pharmaceuticals

CGI (formerly Cellular Genomics Inc.), established at Yale University, began operations in 2000. CGI collaborates with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), employing a unique chemical genetics approach known as "ASKA" (Analog Sensitive Kinase Alleles) to understand kinase function. CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapies for a wide range of oncology and allergy/autoimmunity/inflammatory disease (AAID) indications. The company’s fully integrated drug discovery infrastructure includes proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, and expertise in drug metabolism/pharmacokinetics (DMPK). Leveraging its comprehensive chemical capabilities, CGI has generated a proprietary library of over 50,000 small molecule kinase inhibitors (all compounds designed and synthesized by CGI). To date, CGI has been granted eight U.S. patents covering its novel series of kinase inhibitors. Additionally, all three of CGI's drug discovery and development programs are based on hits obtained from the CGI library.